Results 71 to 80 of about 17,035 (191)

Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
In cardiac cells, Plin5/AMPK regulate lipid homeostasis; excess CD36‐mediated uptake drives lipotoxicity, mitochondrial dysfunction, and CVDs (e.g., heart failure). Biomarkers (ApoB/ApoA‐1) and therapies (SGLT2 inhibitors) target this cascade. ABSTRACT Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation ...
Peiyun Xie, Qun Zeng, Hongrui Wang, Meihua She   +3 more
wiley   +1 more source

Role of Proprotein Convertases in Prostate Cancer Progression

Neoplasia, 2012
Better understanding of the distinct and redundant functions of the proprotein convertase (PC) enzyme family within pathophysiological states has a great importance for potential therapeutic strategies. In this study, we investigated the functional redundancy of PCs in prostate cancer in the commonly used androgen-sensitive LNCaP and the androgen ...
Frédéric Couture, François D'Anjou, Roxane Desjardins, François Boudreau, Robert Day   +4 more
openaire   +3 more sources

Mouse Models of Human Proprotein Convertase Insufficiency

Endocrine Reviews, 2020
AbstractThe kexin-like proprotein convertases perform the initial proteolytic cleavages that ultimately generate a variety of different mature peptide and proteins, ranging from brain neuropeptides to endocrine peptide hormones, to structural proteins, among others.
Manita Shakya, Iris Lindberg
openaire   +3 more sources

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7403-7415, August 2026.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Elevated serum galectin‐3 levels predict the incidence of type 2 diabetes mellitus in a Japanese general population: A 10‐year follow‐up study

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1400-1408, August 2026.
Elevated serum galectin‐3 levels are associated with the incidence of T2DM independent of insulin resistance, particularly among non‐obese individuals. There may be a diabetogenic mechanism that is not mediated by obesity or insulin resistance. ABSTRACT Aims/Introduction Although several studies have reported elevated serum galectin‐3 levels in type 2 ...
Harumi Takubo‐Yoshimura, Mika Enomoto, Ako Fukami, Nagisa Morikawa, Yume Nohara‐Shitama, Hiromi Sato, Mayo Shimoyama‐Yamamoto, Hisashi Adachi, Yoshihiro Fukumoto   +8 more
wiley   +1 more source

Polyphenols with indirect proprotein convertase inhibitory activity

International Journal of Oncology, 2013
Polyphenols, a class of natural products, have been shown to exhibit cancer protective properties. Proprotein convertases form a family of mammalian subtilisin-like serine endoproteases. Increased expression of these enzymes has been associated with numerous pathologies including cancer.
Jingjing, Zhu, Wim, Van de Ven, Alphons, Vermorken   +2 more
openaire   +3 more sources

Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

Journal of Clinical and Preventive Cardiology, 2017
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj   +1 more source

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Vascular Health and Risk Management, 2017
Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of ...
Catapano AL, Pirillo A, Norata GD
doaj  

PCSK9: a convertase that coordinates LDL catabolism

Journal of Lipid Research, 2009
The identification and characterization of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) have provided new insights into LDL metabolism and the causal role of LDL in coronary heart disease (CHD).
Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs   +2 more
doaj   +1 more source

Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors

International Journal of Biological Sciences, 2010
Proprotein convertases are enzymes that proteolytically cleave protein precursors in the secretory pathway to yield functional proteins. Seven mammalian subtilisin/Kex2p-like proprotein convertases have been identified: furin, PC1, PC2, PC4, PACE4, PC5 ...
Sun Tian, Wu Jianhua
doaj